178 related articles for article (PubMed ID: 7671262)
1. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma.
Krajewski S; Blomqvist C; Franssila K; Krajewska M; Wasenius VM; Niskanen E; Nordling S; Reed JC
Cancer Res; 1995 Oct; 55(19):4471-8. PubMed ID: 7671262
[TBL] [Abstract][Full Text] [Related]
2. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer.
Sjöström J; Blomqvist C; von Boguslawski K; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Wist E; Valvere V; Takayama S; Reed JC; Saksela E
Clin Cancer Res; 2002 Mar; 8(3):811-6. PubMed ID: 11895913
[TBL] [Abstract][Full Text] [Related]
3. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas.
Krajewska M; Moss SF; Krajewski S; Song K; Holt PR; Reed JC
Cancer Res; 1996 May; 56(10):2422-7. PubMed ID: 8625322
[TBL] [Abstract][Full Text] [Related]
4. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
[TBL] [Abstract][Full Text] [Related]
5. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
7. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
9. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
10. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.
Schuyer M; van der Burg ME; Henzen-Logmans SC; Fieret JH; Klijn JG; Look MP; Foekens JA; Stoter G; Berns EM
Br J Cancer; 2001 Nov; 85(9):1359-67. PubMed ID: 11720475
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers.
Krajewski S; Thor AD; Edgerton SM; Moore DH; Krajewska M; Reed JC
Clin Cancer Res; 1997 Feb; 3(2):199-208. PubMed ID: 9815673
[TBL] [Abstract][Full Text] [Related]
12. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse.
Giatromanolaki A; Sivridis E; Stathopoulos GP; Fountzilas G; Kalofonos HP; Tsamandas A; Vrettou E; Scopa C; Polychronidis A; Simopoulos K; Koukourakis MI
Anticancer Res; 2001; 21(1A):253-9. PubMed ID: 11299743
[TBL] [Abstract][Full Text] [Related]
13. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation.
Trask DK; Wolf GT; Bradford CR; Fisher SG; Devaney K; Johnson M; Singleton T; Wicha M
Laryngoscope; 2002 Apr; 112(4):638-44. PubMed ID: 12150516
[TBL] [Abstract][Full Text] [Related]
14. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
[TBL] [Abstract][Full Text] [Related]
15. Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities.
Sarbia M; Stahl M; Fink U; Willers R; Seeber S; Gabbert HE
Clin Cancer Res; 1998 Dec; 4(12):2991-7. PubMed ID: 9865911
[TBL] [Abstract][Full Text] [Related]
16. Image cytometric bcl-2:bax and bcl-2:bcl-x ratios in invasive breast carcinoma: correlation with prognosis.
Schiller AB; Clark WS; Cotsonis G; Lawson D; DeRose PB; Cohen C
Cytometry; 2002 Aug; 50(4):203-9. PubMed ID: 12210599
[TBL] [Abstract][Full Text] [Related]
17. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas.
Sinicrope FA; Hart J; Hsu HA; Lemoine M; Michelassi F; Stephens LC
Clin Cancer Res; 1999 Jul; 5(7):1793-804. PubMed ID: 10430084
[TBL] [Abstract][Full Text] [Related]
18. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
19. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
Kornblau SM; Vu HT; Ruvolo P; Estrov Z; O'Brien S; Cortes J; Kantarjian H; Andreeff M; May WS
Clin Cancer Res; 2000 Apr; 6(4):1401-9. PubMed ID: 10778970
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
